• Profit in third quarter of FY2026 up from the corresponding quarter last year; PBT of RM36.68 million and PAT of RM27.98 million in Q3FY2026 increased 23.6% and 24.0% respectively compared to Q3FY2025
  • Cumulative performance across first three quarters improves year-on-year; PBT and PAT for YTD FY2026 rise 29.3% and 29.5% respectively compared to first three quarters of FY2025, despite revenue dipping 2.1% to RM692.29 million in 9M FY2026
  • Robust profit performance across the three quarters also sees PBT (RM116.39 million) and PAT (RM88.56 million) in 9M FY2026 exceed the full-year PBT (RM114.91 million) and PAT (RM87.46 million) for FY2025

Kuala Lumpur, 17 November 2026 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) saw robust year-on-year profit growth in the third quarter ended 30 September 2026, with cumulative Profit Before Tax (“PBT”) and Profit After Tax (“PAT”) in the first three quarters of FY2026 growing 29.3% and 29.5% respectively compared to the previous year, despite revenue declining 2.1% year-on-year to RM692.29 million in the same period. Meanwhile, revenue in the third quarter of FY2026 stands at RM210.05 million.

The Group’s financial performance in Q3FY2026 reflects a significant improvement in profitability, with the cumulative PBT of RM116.39 million across the three quarters already exceeding the full-year PBT for FY2025 at RM114.91 million. Similarly, PAT of RM88.56 million in the same three quarters exceeded full year PAT for FY2025 at RM87.46 million. Comparing year-on-year performance in Q3FY2026, PBT increased 23.6% to RM36.68 million, and PAT rose 24.0% to RM27.98 million, respectively, from Q3FY2025.

The performance across the quarter was achieved through a favourable product mix, continued operational efficiencies, including from manufacturing, and lower input costs. This was further supported by stronger export performance, which recorded double-digit growth. Despite marginally lower cumulative revenue year-on-year, primarily attributable to the normalisation of public sector insulin sales following one-off exceptional uptake in the first half of FY2025, Duopharma Biotech maintained operating resilience, with diversified revenue streams, established presence in the public healthcare sector and continued growth in private market and export segments, alongside stronger contributions from the Ethical Specialty and Consumer Healthcare businesses.

Duopharma Biotech Group Chief Executive Officer Wan Amir-Jeffery Wan Abdul Majid commented, “At Duopharma Biotech, we maintain a positive outlook for the domestic pharmaceutical industry in light of the Government’s ongoing policies. The 2.52% increase in healthcare allocation to RM47.7 billion under Budget 2027, coupled with sales tax relief on eligible pharmaceutical manufacturing inputs and local equipment purchases are positive indicators for domestic pharmaceutical manufacturers. This complements the prioritisation of domestic manufacturing capabilities and national medicine supply security outlined under the 13th Malaysia Plan and the New Industrial Master Plan 2030.”

“The Group remains focused on strengthening our market position, reinforcing competitiveness and nurturing sustainable growth, through long-term supply arrangements, product portfolio expansion, commercial excellence and enhancement of our manufacturing capabilities, as well as by improving operational efficiencies and cost optimisation. Our efforts to strengthen supply chain resilience will continue to focus on effective inventory management and close collaboration with key suppliers to safeguard production continuity,” he added. 

An eye on portfolio expansion

Duopharma Biotech maintains earnings visibility as an established supplier to the Ministry of Health (“MOH”). Currently, it holds a three-year contract to supply Recombinant Human Insulin (“RHI”) to MOH facilities until 2 June 2029, valued at approximately RM155.3 million, as well as two separate two-year contracts to supply MOH facilities, one for Insulin Aspart until 5 February 2028, valued at approximately RM52.5 million, and one for Insulin Glargine until 2 August 2028, valued at approximately RM18 million. 

Recently, the Group signed a five-year exclusive agreement with Taiwan-based Enimmune for the distribution and sale of vaccines in Malaysia, beginning with the exclusive distribution of the EnVAX-A71 vaccine for Hand, Foot and Mouth Disease, in Malaysia, Singapore and Brunei.

Duopharma Biotech also holds contracts to supply pharmaceutical and non-pharmaceutical products under the Approved Products Purchase List to MOH facilities, with 100 products supplied until 31 December 2026 valued at RM684.15 million, and 97 products to be supplied from 1 January to 30 June 2027.

Dividend paid

In Q3 FY2026, Duopharma Biotech paid an interim dividend of 1.5 sen per share (2025: first interim dividend of 1.5 sen per share) equivalent to RM14.43 million (2025: RM 14.43 million) in respect of financial year ending 31 December 2026. The Directors did not recommend any interim dividend for the current quarter ended 30 September 2026. (2025: Nil).

An active industry stakeholder

Duopharma Biotech has continued efforts to advance the Halal pharmaceutical industry, most recently jointly organising the Halal Pharmaceutical Symposium 2026 with MAIWP International University (“UniMAIWP”), wholly owned by Majlis Agama Islam Wilayah Persekutuan (“MAIWP”) under the Prime Minister’s Department, with participation from the Halal Development Corporation.

The Company was recently recognised at the Pharma Industry Awards 2026 organised by the Malaysian Organisation of Pharmaceutical Industries (“MOPI”), where it took home three awards, in the categories of ‘Digital & AI Excellence: Most Progressive Digital & AI Initiatives’, ‘Highest Capital Investment: Total Sales Above RM150 Million’ and ‘Productivity Excellence: Prescription Medicine’. Duopharma Biotech also received the 2027 Graduates’ Choice of Employers to Work For in the Pharmaceutical and Biotechnology categories at the Talentbank’s 9th Graduates’ Choice Award.